• where experts go to learn about FDA
    • More Kryptonite for KratomNovember 13th, 2018

      Most people think of getting salt water taffy from resort beach town Myrtle Beach, SC. But, apparently, there is more activity going on in Myrtle Beach: a company there was supplying customers with kratom, a substance that the government contends is an illegal dietary supplement. …

    • HP&M to Co-Host “DEA Compliance During the Opioid Epidemic” WebinarNovember 12th, 2018

      Hyman, Phelps & McNamara, P.C. is co-hosting a complimentary webinar, with Five Rivers Rx, on DEA compliance during the current opioid epidemic. The webinar is scheduled for November 15, 2018 (3:00-4:00 PM ET) and is geared especially towards DEA-registered manufacturers, distributors, importers, exporters and practitioners. The …

    • FDA Finalizes One Guidance and Issues a Draft Guidance Related to the Amended Nutrition Labeling RegulationsNovember 12th, 2018

      Last week FDA published a final guidance and a draft guidance related to the nutrition labeling regulation amendments published in 2016. Final guidance The Guidance, titled “Nutrition and Supplement Facts Labels: Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of …

    • Recruiting Class of 2018 – HP&M Adds Three New Attorneys and Two Regulatory ProfessionalsNovember 8th, 2018

      It’s been a busy year at Hyman, Phelps & McNamara P.C. as we’ve added three new attorneys and two regulatory professionals to our ranks.  The five professionals collectively add depth and breadth to our practice with FDA and industry experience. Deborah L. Livornese joined HP&M as …

    • HP&M Takes Home 2019 “Law Firm of the Year in FDA Law” Honors from U.S. News and Best LawyersNovember 8th, 2018

      Hyman, Phelps & McNamara, P.C. (“HP&M”) has once again been ranked as a “Tier 1” law firm in the area of “FDA Law” (both nationally and in Washington, D.C.) by the folks over at U.S. News & World Report, who teamed up with Best Lawyers …

    • May FDA Regulate Medical Devices As If They Were Drugs?November 8th, 2018

      In the world of FDA, there is a stark divide between the regulatory treatment of drugs and medical devices. A product intended to diagnose or treat disease, or to alter the structure or function of the body, is within the definition of a drug under …

    • Trump Administration Takes a Turn at Medicare Part B Payment ReformNovember 7th, 2018

      On October 30, 2018, the Centers for Medicare and Medicaid Services (CMS) issued an Advanced Notice of Proposed Rulemaking (ANPRM) soliciting public feedback on a potential International Pricing Index (IPI) Model for payment of certain drugs covered under Medicare Part B. 83 Fed. Reg. 54546 …

    • HP&M Director Larry Houck Receives NASCSA President’s AwardNovember 6th, 2018

      Last week during the 34th annual National Association of State Controlled Substances Authorities (“NASCSA”) conference in Scottsdale, Arizona, Hyman, Phelps & McNamara, P.C. (“HP&M”) Director Larry Houck was honored with the organization’s 2018 President’s Award. NASCSA provides a forum for state, federal and local regulators, …

    • HRSA Releases Proposed Rule to Move Up Effective Date of 340B Final RuleNovember 6th, 2018

      On November 2, 2018, the Health Resources and Services Administration (“HRSA”) released a proposed rule to move up to January 1, 2019 the effective date of implementation and enforcement of the previously delayed final rule implementing the 340B Drug Discount Program (“Final Rule”). The Final …

    • The Obesity Epidemic: FDA’s Waistline Continues to Expand!November 5th, 2018

      Waaaaayyyy back in 2012, when life (and practicing food and drug law) was simpler, something caused us to study and evaluate the year-over-year change (i.e., the change in girth by the number of pages) in Title 21 of the Code of Federal Regulations (“CFR”) from …

    • HP&M Weighs in on FDA’s “Technical Assistance” to Proposed IVD LegislationNovember 2nd, 2018

      It’s been about two months since FDA issued its Technical Assistance (TA), and the buzz around FDA’s draft legislation has not died down. In fact, FDA has continued to promote the proposal, including a speech by Commissioner Gottlieb’s Chief of Staff, Lauren Silvas, in late …

    • Relief At Last? DC Circuit Rules on Rx PEG-3350 ANDAsNovember 1st, 2018

      Only ten years after initiating the withdrawal process, FDA approval for prescription PEG-3350 is officially withdrawn. The D.C. Circuit issued an unpublished opinion this week affirming FDA’s April 2018 Order withdrawing approval for several PEG-3350 ANDAs and denying requests for a hearing by the affected …